If the discordant results come from the difference in LOD between the tests, the tumors harboring the mutation would not be predominant in the whole tumor when the assumed tumor content was not overestimated, therefore poor EGFR-TKI efficacy is expected in these cases. The gene discussed is EGFR; the disease is neoplasm.